Novavax (NVAX) : 6 investment research analysts covering Novavax (NVAX) have an average price target of $13.15 for the near short term. The highest target price given by the Brokerage Firm to the stock is $17 and the lowest target is $6 for the short term. Analysts expect the variance to be within $3.81 of the average price.
Novavax (NVAX), A reduction of 2,847,155 shares or 4.3% was observed in the short interest of Novavax, Inc. The interest on June 30,2016 came in at 63,030,174 shares and as per the average daily trading of 5,807,742 shares, the days to cover are 11. The reduced interest is 24.1% of the floated shares. The data of June 15,2016 put the interest at 65,877,329 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.
Also, Chardan Capital initiates coverage on Novavax (NASDAQ:NVAX) The current rating of the shares is Neutral. Equity Analysts at the Firm announces the price target to $5.75 per share. The rating by the firm was issued on April 4, 2016.
Novavax (NASDAQ:NVAX): stock turned positive on Thursday. Though the stock opened at $7.48, the bulls momentum made the stock top out at $7.7 level for the day. The stock recorded a low of $7.46 and closed the trading day at $7.55, in the green by 1.62%. The total traded volume for the day was 3,702,997. The stock had closed at $7.43 in the previous days trading.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).